RecruitingPhase 1Phase 2NCT07281781
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
Sponsor
University of California, Irvine
Enrollment
10 participants
Start Date
Sep 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Nelfinavir for people with myelofibrosis and myelofibrosis; anemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNelfinavir
Taken twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07281781
Related Trials
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT0532019828 locations
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
NCT072506463 locations
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT0755142724 locations
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
NCT0653381327 locations
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
NCT070205333 locations